You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

LEXIVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lexiva patents expire, and when can generic versions of Lexiva launch?

Lexiva is a drug marketed by Viiv Hlthcare and is included in two NDAs.

The generic ingredient in LEXIVA is fosamprenavir calcium. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lexiva

A generic version of LEXIVA was approved as fosamprenavir calcium by MYLAN on April 15th, 2016.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LEXIVA?
  • What are the global sales for LEXIVA?
  • What is Average Wholesale Price for LEXIVA?
Drug patent expirations by year for LEXIVA
Drug Prices for LEXIVA

See drug prices for LEXIVA

Recent Clinical Trials for LEXIVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical College of WisconsinPhase 3
ViiV HealthcarePhase 1
GlaxoSmithKlinePhase 1

See all LEXIVA clinical trials

Paragraph IV (Patent) Challenges for LEXIVA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LEXIVA Tablets fosamprenavir calcium 700 mg 021548 1 2012-01-18

US Patents and Regulatory Information for LEXIVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LEXIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare LEXIVA fosamprenavir calcium SUSPENSION;ORAL 022116-001 Jun 14, 2007 ⤷  Sign Up ⤷  Sign Up
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 ⤷  Sign Up ⤷  Sign Up
Viiv Hlthcare LEXIVA fosamprenavir calcium TABLET;ORAL 021548-001 Oct 20, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LEXIVA

See the table below for patents covering LEXIVA around the world.

Country Patent Number Title Estimated Expiration
Slovenia 1098898 ⤷  Sign Up
Australia 5037999 ⤷  Sign Up
Tunisia SN99145 CALCIUM (3S) TETRAHYDRO-3-FURANYLE (1S,2R)-3-[[4-AMINOPHENYLE) SULFONYLE] ISOBUTYLE)AMINO]-1-BENZYLE-2-(PHOSPHONOOXY), PROPYLCARBAMATE ⤷  Sign Up
Japan 2009102400 PRODRUG OF ASPARTYL PROTEASE INHIBITOR ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LEXIVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0933372 324 Finland ⤷  Sign Up
0933372 SPC/GB08/018 United Kingdom ⤷  Sign Up PRODUCT NAME: FOSAMPRENAVIR CALCIUM: ((1S,2R)-3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-1-(PHENYLMETHYL)-2(PHOSPHONOOXY)PROPYL)-CARBABAMIC ACID C-((3S)-TETRAHYDRO-3-FURANYL) ESTER CALCIUM SALT; REGISTERED: UK EU/1/04/282/001 20040712; UK EU/1/04/282/002 20040712
0933372 300339 Netherlands ⤷  Sign Up 300339, 20180310, EXPIRES: 20190711
0933372 SPC012/2008 Ireland ⤷  Sign Up SPC012/2008: 20091119, EXPIRES: 20190711
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.